Please try another search
For the fiscal year ended 31 December 2021, Sun Bio Inc revenues increased 83% to W9.96B. Net income decreased 76% to W284.7M. Revenues reflect P1PAL-20 segment increase of 84% to W4.51B, PEG-filgrastim segment increase of 44% to W2.94B, India (Country) segment increase of 59% to W7.36B, Other Countries segment increase of 22% to W544.9M. Net income was offset by Finance Expense increase from W742.7M to W2.85B (expense).
Period Ending: | Dec 31, 2014 |
---|---|
Total Revenue | |
Gross Profit | |
Operating Income | |
Net Income |
Period Ending: | Dec 31, 2014 |
---|---|
Total Assets | 4926.23 |
Total Liabilities | 383.37 |
Total Equity | 4542.87 |
Period Ending: | Dec 31, 2014 |
---|---|
Period Length: | 0 Months |
Cash From Operating Activities | |
Cash From Investing Activities | |
Cash From Financing Activities | |
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review